Direct activation of atiii in whole blood and plasma
A technology for thrombosis and blood products, applied in the field of direct activation of ATIII in whole blood and plasma, which can solve the problem that patients cannot bear HAART treatment, pill volume and drug-drug interaction limitations, and the use period of retroviral drug combination therapy Difficulty for a long time
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0066] Example 1: Protocol for ATIII activation in vitro using standard, unfractionated heparin
[0067] Standard, unfractionated heparin for humans (1,000-10,000 units, or about 2 to about 40 mg) was added to 500 mL of a commercially available human plasma sample (containing an average of about 120 to about 150 mg of ATIII). The amount of heparin added to the bag depends on the patient's viral load and desired treatment modality. The resulting mixture was incubated at room temperature, 37°C or 40°C for 24-72 hours. Light mixing is required during the incubation period. The incubated mixture can be further purified to remove unreacted heparin, or it can be infused into the patient without purification. In this method, the heparin dose is much lower compared to the ATIII level in plasma, thus avoiding free heparin in the product mixture, thus reducing the risk of bleeding.
Embodiment 2
[0068] Example 2: Protocol for ATIII Activation in In Vitro Blood Using Standard, Unfractionated Heparin
[0069] Standard, unfractionated heparin for humans (1,000-20,000 units, or about 2 to about 40 mg) was added to 1,000 mL of blood samples from HIV or HCV patients (with mean about 70 to about 150 mg of ATIII). The resulting mixture was incubated at room temperature, 37°C or 40°C for 24-72 hours. Light mixing is required during the incubation period. The incubated mixture can be further purified to remove unreacted heparin, or it can be infused into the patient without purification. In this method, the heparin dose is much lower compared to the ATIII level in plasma, thus avoiding free heparin in the product mixture, thus reducing the risk of bleeding.
Embodiment 3
[0070] Example 3: Protocol for ATIII activation in plasma in vitro using low molecular weight heparin
[0071] Low molecular weight (LMW) heparin for humans (1,000-10,000 units, or about 2-about 20 mg) was added to 500 mL of commercially available human plasma samples (containing an average of about 70 to about 150 mg of ATIII). The resulting mixture was incubated at room temperature, 37°C or 40°C for 24-72 hours. Light mixing is required during the incubation period. The incubated mixture can be further purified to remove unreacted heparin, or it can be infused into the patient without purification. In this method, the heparin dose is much lower compared to the ATIII level in plasma, thus avoiding free heparin in the product mixture, thus reducing the risk of bleeding.
PUM
| Property | Measurement | Unit |
|---|---|---|
| molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More